Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
Not yet recruiting · NCT07840443 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma | Early Stage Endometrial Cancer; Estrogen Receptor-positive | Not yet recruiting | Phase 2 | 2026-09-25 | NCT07840443 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Health Network, Toronto | 417 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BC Cancer - Vancouver | Vancouver | Canada | 15 |
| Hôpital Maisonneuve-Rosemont | Montreal | Canada | 13 |
| Jewish General Hospital | Montreal | Canada | 130 |
| Kingston Health Sciences Centre | Kingston | Canada | 91 |
| Princess Margaret Cancer Centre/University Health Network | Toronto | Canada | 1 |
| The Ottawa Hospital | Ottawa | Canada | 47 |